Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Abbott (NYSE:ABT) won 510(k) clearance from the FDA for its FreeStyle InsuLinx blood glucose monitor, its first to include a touch-screen interface, automated logbook and personalization features.
U.S. Attorney’s office for Massachusetts dropped a years-long inquiry into allegations that Medtronic (NYSE:MDT) promoted off-label use for its biliary stents.
The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody’s Investor Services, according to a report by the ratings agency.